U.S. stock market midday update: Argenx's earnings report exceeded expectations, rising 7.46%, analysts support target price

U.S. Stock Market Midday Update

Argenx rose 7.46%, with increased trading volume. Based on recent key news:

1. On July 23, Argenx released its second-quarter financial report, showing a GAAP earnings per share of $7.32, exceeding expectations by $1.12, with revenue increasing 60% year-over-year to $1.52 billion, and significant improvement in cash flow. This strong financial performance drove the stock price up. Source: Argenx Company Announcement

2. On July 23, analysts from Bernstein and Deutsche Bank maintained a buy rating on Argenx, with target prices of €877 and €900, respectively. The analysts' positive ratings boosted market confidence, further driving the stock price up. Source: Bernstein and Deutsche Bank Reports

3. On July 23, Argenx's VYVGART product performed strongly in the MG and CIDP fields, driving sales growth. The successful expansion of the product and pipeline progress supports the company's future growth. Source: Argenx Company Announcement. The healthcare industry is experiencing strong growth, with significant capital inflow.

Stocks with High Trading Volume in the Industry

AbbVie rose 1.14%. Based on recent key news:

1. On July 23, Canaccord Genuity raised AbbVie's target price from $273 to $282, maintaining a "buy" rating. This positive analyst rating boosted market confidence in AbbVie, driving the stock price up.

2. On July 22, MarketBeat pointed out that although AbbVie currently has a "moderate buy" rating among analysts, top analysts believe there are five stocks that are more worthy of purchase. This may have some impact on AbbVie's market appeal.

3. On July 22, analysts considered AbbVie a good long-term holding option, a view that may further support the stock price increase. Market capital inflow and stable industry performance.

Amgen rose 0.75%. Based on recent news:

1. On July 22, Amgen's annualized return over the past 15 years was 13.64%, outperforming the market. Significant returns for long-term investors enhanced market confidence, driving the stock price up.

2. On July 21, the U.S. Tax Court may make a ruling on Amgen's tax case this year. Investors have concerns about potential tax risks, but the transparency of the case's progress has improved market confidence.

3. On July 21, Amgen's main products Prolia and Repatha performed well in sales, and the market is optimistic about their future growth, further driving the stock price up. The market is optimistic about Amgen's long-term performance and product sales expectations.

Regeneron Pharmaceuticals fell 0.09%. Based on recent key news:

1. On July 22, Hagens Berman Law Firm launched an investigation into Regeneron Pharmaceuticals regarding company liability issues. This move may lead to investor concerns, affecting the stock price

2. On July 21, analysts rated Regeneron Pharmaceuticals as "Moderate Buy," but it was not included in the recommended list, affecting market confidence.

3. On July 21, Telix Pharmaceuticals' strategic partnership with Regeneron Pharmaceuticals supports its full-year revenue expectation of over $1 billion. Despite the positive collaboration, it failed to boost the stock price. The pharmaceutical industry is currently facing regulatory risks.

Stocks Ranked Among the Top by Market Capitalization in the Industry

Gilead Sciences rose by 0.13%. Based on recent key news:

1. On July 22, Gilead Sciences announced that its BDR program in Brazil will undergo a mandatory stock split, changing the ratio from 1:2 to 1:12. This change may lead to increased market demand for the stock, driving up its price.

2. On July 21, Leerink Partners downgraded Gilead Sciences' rating from "Outperform" to "Market Perform," and lowered the target price from $146 to $127. This move reflects market concerns about its HIV preventive medication market growth, putting pressure on the stock price.

3. On July 22, Gilead Sciences expects its second-quarter financial report to include $11.2 billion in internal R&D asset expenses, which may significantly impact its financial performance and attract investor attention. The pharmaceutical industry is facing growth pressures and requires close monitoring